

# CPH Group AG

Switzerland | Industrial Goods & Services

## 1HFY25 Results update


22 July 2025

### Company Data

Price:	CHF 75.00
Market Cap:	CHF 449.5mn
Free Float:	69.4%
No. of shares:	6.0mn
Avg. traded volume (30 day):	1,213
Bloomberg:	CPHN SW
Reuters:	CPHN-EB
ISIN:	CH0001624714

Source: SIX Swiss Exchange and Bloomberg

### Share Price Development



Source: Bloomberg

### Key Financial Data

	2023	2024	2025E	2026E
Sales	361.5	323.3	344.7	367.1
EBITDA %	18.0%	16.6%	17.0%	17.3%
EBIT %	14.4%	12.1%	12.7%	13.1%
Net Margin %	12.5%	10.7%	10.2%	10.6%
Basic EPS	7.5	5.7	5.8	6.5
Diluted EPS	7.5	5.7	5.8	6.5
DPS	4.0	2.0	2.0	2.5
Equity Ratio %	72.9%	63.0%	65.9%	68.0%
Capex	(3.1)	(18.5)	(29.5)	(18.4)
P/Sales	1.1x	1.2x	1.3x	1.3x
P/E	8.8x	11.5x	13.1x	11.8x
EV/EBITDA	4.3x	5.3x	8.3x	7.7x

Source: Research Dynamics, Company data

### Next Events

Investor Day	16 Sep 2025
Investor Equity Conference	17 Sep 2025
Annual Results	18 Feb 2026

### Analysts

Doris Rudischhauser  
dru@researchdynamics.ch

Alexandre Müller  
amu@researchdynamics.ch

Tel: +41 43 268 3232

[www.researchdynamics.ch](http://www.researchdynamics.ch)

## Advancing global expansion strategy and focus on operational efficiency

### Muted results amid mixed market trends

CPH Group (CPH) reported net sales of CHF 176.0 mn for 1HFY25, marginally down by 0.5% year-on-year (YoY) or down 5.1% organically as 8.2% growth from acquisitions was offset by 3.5% FX headwinds. EBITDA remained unchanged at CHF 30.2 mn, resulting in an EBITDA margin of 17.2% (1H24: 17.1%), impacted by FX headwinds, an unfavourable product mix and a higher cost base following the spin-off of the Paper Division. Group EBIT declined 6.8% YoY to CHF 21.9 mn, with the margin narrowing to 12.5% (1H24: 13.3%) due to higher acquisition-related depreciation and amortisation. The net result came in at CHF 17.1 mn, down CHF 4.0 mn YoY, reflecting the absence of prior-year one-off gains and increased financial expenses from recent acquisitions. Free cash flow before acquisitions was CHF -1.8 mn due to seasonal working capital requirements. Net debt stood at CHF 30.3 mn with a solid equity ratio of 54.3%.

### Segmental performance

**Zeochem:** Net sales declined 7.2% YoY to CHF 57.5 mn in (-8.3% organically), impacted by lower lithium prices, cautious customer ordering, weaker demand for industrial gas molecular sieves, and adverse FX effects. Although demand remained strong for high-value molecular sieves and deuterated solvents, demand for industrial gas sieves lagged prior-year levels. Additionally, overcapacity in China has led to ongoing pricing and margin pressure across the molecular sieve market. EBITDA rose 17.4% YoY to CHF 12.2 mn, with the margin expanding to 21.2% (1H24: 16.7%), while EBIT increased 15.0% YoY to CHF 8.0 mn (1H24: CHF 7.0 mn), with the corresponding margin at 14.0% (1H24: 11.3%). The ongoing integration of Sorbchem India is progressing as planned and supporting regional growth, with capacity utilisation remaining high at key production sites in Rüti and Louisville. Headcount grew 9.8% YoY to 393 FTEs during the period.

**Perlen Packaging:** Net sales increased 3.1% YoY to CHF 118.4 mn, though declined 3.4% on an organic, constant-currency basis. During the period, Perlen Packaging saw higher capacity utilisation across sites in Switzerland, Germany, and China, while sales volumes at its Brazilian plant nearly doubled YoY. With customer destocking largely complete, order volumes recovered compared to prior year period, while PVC prices remained stable albeit at elevated levels following the pandemic. EBITDA fell 12.6% YoY to CHF 17.8 mn (1H24: CHF 20.4 mn), with the corresponding margin narrowing to 15.0% (H1 2024: 17.8%), impacted by FX headwinds, an unfavourable product mix, and higher costs following the Paper Division spin-off. EBIT fell by a more significant 20.2% to CHF 13.6 mn (1H24: CHF 17.1 mn), with the EBIT margin decreasing to 11.5% (1H24: 14.9%) due to higher acquisition-related depreciation and amortisation.

### Outlook for FY2025

The first half of 2025 was characterised by an unfavourable economic climate, with mounting geopolitical tensions and trade disputes fuelling uncertainty and hindering global economic growth. This caused many companies to postpone orders and investments. CPH Group also experienced the impact of slowing demand in its key markets and the weaker US dollar. Although the outlook for the second half is encouraging, the environment remains volatile amid ongoing economic and geopolitical challenges.

**Group:** Despite ongoing economic and geopolitical uncertainties, the outlook for the second half of 2025 remains positive. The CPH Group reaffirms its initial projections for the year and continues to anticipate a modest improvement in both earnings and net results compared to 2024.

**Zeochem:** The integration of Sorbchem and SiliCycle, along with capacity upgrades in Rüti and process improvements in the US, is scheduled for implementation in FY2025. Although net sales for the year are expected to be lower than in 2024, EBITDA is anticipated to exceed last year's levels.

**Perlen Packaging:** Perlen Packaging expects to see continued growth in new order volumes in 2HFY25 compared to the same period last year, thanks to the planned launch of a fully automated packaging plant in Brazil. Full-year 2025 net sales are expected to exceed 2024 levels, with EBITDA projected to remain broadly in line with the previous year.

#### **Mid-term Outlook:**

CPH has raised its mid-term outlook, which underpins the company's strategy to expand its geographic and product footprint, and augment its product mix. The company expects annual net sales growth of 5-8%, an EBITDA margin in the range of 16-18%, and a free cash flow margin of 8-10%. The company aims to keep the equity ratio above 50%. And, in addition to the projected organic sales growth of 5-8% p.a., external growth via acquisitions remains a key pillar of the growth strategy.

#### **Other Highlights**

**Acquisition of SiliCycle:** In July 2025, Zeochem signed an agreement to acquire the core assets of SiliCycle, a Canadian company that specializes in chromatography gels. This deal will enable Zeochem to expand its range of products with high-value offerings and strengthen its position in fast-growing specialty markets. The acquisition supports Zeochem's strategy to expand in higher-margin segments and is expected to close in the third quarter of FY25.

#### **Valuation and conclusion**

The Packaging and Chemistry divisions offer a favourable long-term outlook, and the operating results of these divisions are expected to remain resilient. Apart from a supportive outlook, the cost optimisation efforts are expected to result in margin improvement for the EBITDA margins to remain in the 16-18% range going forward, which should lead to solid earnings growth.

We value CPH using DCF and relative valuation techniques. Our intrinsic value of CHF 92.5 per share implies an upside of 23.3% from current levels. For relative valuation, since the Group operates in two entirely different divisions, we compare CPH's divisions with various sets of relevant industry peers. We have employed three parameters – EV/EBITDA, P/S, and P/E – to analyse the relative valuation of the Group. CPH currently trades at an EV/EBITDA multiple of 8.3x (FY2025e), a 29.0% discount to the weighted average multiple of division peers.

**Exhibit 1: CPH – Comparison with division peers**

Company	EV/EBITDA			P/S			P/E		
	3 year average	CY2025E	CY2026E	3 year average	CY2025E	CY2026E	3 year average	CY2025E	CY2026E
CPH Chemie & Paper	3.8x	8.3x	7.7x	0.6x	1.3x	1.3x	11.7x	13.1x	11.8x
<b>Chemistry peers:</b>									
Honeywell International	16.6x	18.0x	16.8x	3.7x	3.9x	3.7x	24.4x	24.0x	22.6x
EMS Chemie	25.3x	24.6x	24.2x	7.0x	7.2x	7.5x	31.9x	33.1x	32.4x
Arkema	5.2x	5.1x	5.7x	0.6x	0.5x	0.5x	11.2x	7.5x	10.1x
Clariant AG	8.1x	6.6x	6.5x	1.0x	0.7x	0.7x	42.1x	10.4x	10.8x
<b>Packaging peers:</b>									
West Pharmaceutical Services	27.9x	20.9x	20.8x	8.2x	5.2x	5.1x	42.5x	31.8x	33.5x
Amcor Plc	10.5x	14.5x	13.0x	1.1x	1.6x	1.5x	18.2x	13.4x	13.0x
Berry Global Group	7.4x	7.0x	7.0x	0.6x	0.6x	0.8x	11.1x	8.9x	9.9x
DS Smith	6.6x	14.2x	13.0x	0.7x	1.2x	1.1x	13.1x	17.2x	21.0x
Gerresheimer AG	10.4x	8.9x	7.8x	1.5x	0.8x	0.7x	28.7x	10.5x	12.5x
Macfarlane Group	6.1x	5.3x	5.3x	0.6x	0.6x	0.5x	11.7x	9.1x	9.4x
Median	9.6x	11.7x	10.6x	1.2x	1.2x	1.2x	18.1x	13.0x	13.5x
High	27.9x	24.6x	24.2x	8.2x	7.2x	7.5x	42.5x	33.1x	33.5x
Low	5.2x	5.1x	5.3x	0.6x	0.5x	0.5x	11.1x	7.5x	9.4x
Premium (disc) to peers	(60%)	(29%)	(28%)	(46%)	8%	3%	(35%)	1%	(12%)

Source: Bloomberg and Thomson Eikon (as on 21 July 2025)

**Exhibit 2: CPH – Comparison with a weighted average of division peers**

	EV/EBITDA			P/S			P/E		
	3 year average	CY2025E	CY2026E	3 year average	CY2025E	CY2026E	3 year average	CY2025E	CY2026E
Chemistry peers	12.4x	12.3x	11.6x	2.3x	2.3x	2.2x	28.1x	17.2x	16.7x
Packaging peers	7.0x	8.0x	7.4x	0.6x	0.7x	0.7x	12.4x	9.8x	11.2x

Source: Bloomberg and Thomson Eikon (as on 21 July 2025)

## DETAILED FINANCIAL STATEMENTS

### Income Statement

CHF mn (except per share)	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Zeochem	73	95	110	124	117	116	124
Paper	210	231	384	262			
Perlen Packaging	162	171	231	237	206	229	243
<b>Net Sales</b>	<b>445</b>	<b>497</b>	<b>725</b>	<b>362</b>	<b>323</b>	<b>345</b>	<b>367</b>
Cost of Sales	(255)	(336)	(431)	(203)	(174)	(179)	(190)
<b>Gross profit</b>	<b>190</b>	<b>161</b>	<b>294</b>	<b>158</b>	<b>149</b>	<b>165</b>	<b>177</b>
Personnel cost	(93)	(92)	(102)	(66)	(67)	(76)	(81)
Outsourced maintenance/repairs	(17)	(18)	(28)	(9)	(8)	(8)	(9)
Other operating expense	(25)	(25)	(34)	(19)	(20)	(22)	(24)
<b>Total operating costs</b>	<b>(135)</b>	<b>(135)</b>	<b>(163)</b>	<b>(94)</b>	<b>(96)</b>	<b>(107)</b>	<b>(113)</b>
<b>EBITDA</b>	<b>55</b>	<b>26</b>	<b>131</b>	<b>65</b>	<b>54</b>	<b>59</b>	<b>64</b>
Depreciation	(29)	(27)	(16)	(12)	(13)	(13)	(13)
Amortization	(1)	(1)	(2)	(1)	(2)	(2)	(2)
<b>Operating profit (EBIT) before impairment</b>	<b>25</b>	<b>(3)</b>	<b>112</b>	<b>52</b>	<b>39</b>	<b>44</b>	<b>48</b>
Impairment	0	(150)	0	0	0	0	0
<b>Operating profit (EBIT)</b>	<b>25</b>	<b>(153)</b>	<b>112</b>	<b>52</b>	<b>39</b>	<b>44</b>	<b>48</b>
Finance costs	(5)	(5)	(4)	(2)	0	(2)	(1)
Finance income	0	1	0	0	0	0	0
<b>Total financial inc/ (exp)</b>	<b>(5)</b>	<b>(4)</b>	<b>(4)</b>	<b>(2)</b>	<b>0</b>	<b>(2)</b>	<b>(1)</b>
<b>Profit before taxes</b>	<b>20</b>	<b>(157)</b>	<b>108</b>	<b>50</b>	<b>40</b>	<b>42</b>	<b>47</b>
Non-operating items	19	7	(8)	8	0	0	0
Income taxes	8	(2)	1	(12)	(7)	(7)	(8)
<b>Profit attributable to the parent</b>	<b>47</b>	<b>(152)</b>	<b>101</b>	<b>45</b>	<b>34</b>	<b>35</b>	<b>39</b>
<b>Basic EPS</b>	<b>7.8</b>	<b>(25.3)</b>	<b>16.8</b>	<b>7.5</b>	<b>5.7</b>	<b>5.8</b>	<b>6.5</b>
<b>Diluted EPS</b>	<b>7.8</b>	<b>(25.3)</b>	<b>16.8</b>	<b>7.5</b>	<b>5.7</b>	<b>5.8</b>	<b>6.5</b>
<b>DPS</b>	<b>1.8</b>	<b>1.3</b>	<b>4.5</b>	<b>4.0</b>	<b>2.0</b>	<b>2.0</b>	<b>2.5</b>

Source: Research Dynamics, Company data

### Balance Sheet

CHF mn	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
<b>Assets</b>							
<b>Non-current assets</b>							
PPE	352.6	196.5	213.7	116.3	128.8	140.4	142.0
Intangible assets	5.6	5.8	4.5	2.6	6.3	9.2	10.6
Long-term financial assets	10.0	10.0	10.0	27.2	27.8	30.6	33.7
Long-term financial receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other non-current assets	64.8	58.4	55.8	0.0	0.0	0.0	0.0
<b>Total non-current assets</b>	<b>432.9</b>	<b>270.7</b>	<b>284.0</b>	<b>146.1</b>	<b>163.0</b>	<b>180.2</b>	<b>186.2</b>
<b>Current assets</b>							
Inventories	78.3	87.5	113.1	72.5	74.8	74.9	81.7
Trade accounts receivable	52.9	69.3	93.9	51.1	48.3	50.1	58.3
Other receivables	17.2	28.5	21.9	18.5	9.7	10.7	11.8
Prepaid exp and accrued income	6.7	9.2	9.6	4.4	5.2	5.7	6.3
Short-term financial receivables	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Liquid funds and Securities	116.3	95.1	143.6	35.4	31.6	31.0	32.7
<b>Total assets</b>	<b>704.2</b>	<b>560.4</b>	<b>666.2</b>	<b>327.9</b>	<b>332.6</b>	<b>352.5</b>	<b>377.0</b>
<b>Shareholders' Equity and Liabilities</b>							
Share capital	1.2	1.2	1.2	0.9	0.9	0.9	0.9
Capital reserves	4.2	(0.1)	(0.1)	(0.5)	(0.5)	(0.5)	(0.5)
Profit reserves	418.5	459.5	397.1	216.3	209.0	197.0	217.0
Net result for the year	46.9	(151.6)	0.0	0.0	0.0	35.0	38.8
<b>Non-current liabilities</b>							
Long-term financial liabilities	109.7	106.6	0.0	0.0	8.0	6.7	6.7
Pension scheme liabilities	1.2	1.4	1.7	0.0	0.0	0.0	0.0
Other long-term liabilities	0.4	0.3	0.0	0.0	0.0	0.0	0.0
Long-term provisions	31.5	24.1	31.4	32.3	33.8	33.8	34.8
<b>Current liabilities</b>							
Trade accounts payable	56.8	84.8	93.0	34.1	34.1	34.0	33.6
Other payables	4.6	3.9	6.5	2.4	2.4	2.4	2.4
Accrued liabilities and deferred income	16.8	18.3	27.2	31.4	31.4	31.4	31.4
Short-term financial liabilities	8.1	3.2	98.9	11.0	11.0	9.2	9.2
Short-term provisions	3.3	7.4	7.8	2.6	2.6	2.6	2.6
<b>Total liabilities</b>	<b>232.4</b>	<b>249.9</b>	<b>266.6</b>	<b>113.7</b>	<b>123.2</b>	<b>120.1</b>	<b>120.7</b>
<b>Total equity and liab.</b>	<b>704.2</b>	<b>560.4</b>	<b>666.2</b>	<b>327.9</b>	<b>332.6</b>	<b>352.5</b>	<b>377.0</b>

Source: Research Dynamics, Company data

### Cash Flow Statement

CHF mn	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Net profit for the period	47.0	(151.4)	101.0	45.1	34.4	35.0	38.8
Non-cash adjustments:	(2.2)	169.5	28.4	9.6	8.1	15.1	15.5
<b>Change in CA and CL:</b>							
(Increase)/ decrease in inventories	(4.1)	(9.6)	(27.2)	3.3	(0.4)	(0.1)	(6.8)
Decrease in trade accounts receivable	20.5	(15.5)	(26.7)	3.6	6.0	(1.8)	(8.3)
Increase/ (decrease) in trade accounts payable	(9.0)	30.7	6.9	(12.0)	(1.7)	(0.1)	(0.4)
Other changes in working capital	2.8	(7.9)	15.3	8.2	6.9	(4.3)	(3.7)
<b>CFO</b>	<b>55.0</b>	<b>15.8</b>	<b>97.6</b>	<b>57.9</b>	<b>53.3</b>	<b>43.9</b>	<b>35.1</b>
Investments in tangible fixed assets	(17.5)	(23.0)	(32.9)	(17.4)	(19.8)	(24.5)	(14.7)
Disposals of tangible fixed assets	5.2	5.2	4.3	14.8	2.0	0.0	0.0
Investments in intangible assets	(1.3)	(1.6)	(1.0)	(0.4)	(0.6)	(5.1)	(3.7)
Sale of subsidiary/ Divestiture of interests	0.1	0.2	0.0	0.0	(32.8)	0.0	0.0
Investments in business activities	(1.6)	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of long-term financial receivables	(0.3)	(0.1)	0.0	(2.4)	0.0	0.0	0.0
<b>CFI</b>	<b>(15.3)</b>	<b>(19.2)</b>	<b>(29.6)</b>	<b>(5.5)</b>	<b>(51.3)</b>	<b>(29.5)</b>	<b>(18.4)</b>
Increase/ (Decrease) in short-term financial liabilities and receivables	(4.4)	(6.9)	(3.2)	4.6	10.2	(1.7)	0.0
Increase/ (Decrease) in long-term financial liabilities	0.0	0.0	(6.5)	(98.7)	7.9	(1.3)	0.0
Increase in other long-term liabilities	(0.4)	(0.3)	(1.3)	0.0	0.0	0.0	0.0
Dividends to shareholders	(10.8)	(10.8)	(7.8)	(27.0)	(24.0)	(12.0)	(15.0)
<b>CFF</b>	<b>(15.6)</b>	<b>(18.0)</b>	<b>(19.0)</b>	<b>(121.7)</b>	<b>(6.4)</b>	<b>(15.0)</b>	<b>(15.0)</b>
Exchange (losses)/gains	(0.9)	0.2	(0.5)	(2.1)	0.5	0.0	0.0
<b>Net change in cash</b>	<b>23.2</b>	<b>(21.2)</b>	<b>48.5</b>	<b>(71.4)</b>	<b>(3.8)</b>	<b>(0.6)</b>	<b>1.7</b>
Opening cash balance	93.1	116.3	95.1	106.8	35.4	31.6	31.0
<b>Closing cash balance</b>	<b>116.3</b>	<b>95.1</b>	<b>143.6</b>	<b>35.4</b>	<b>31.6</b>	<b>31.0</b>	<b>32.7</b>

### Key Ratios

	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
<b>Growth Ratios</b>							
Sales Growth	(15%)	12%	46%	(14%)	(11%)	7%	6%
Chemistry division	(6%)	30%	16%	13%	(6%)	(1%)	7%
Paper division	(29%)	10%	67%	(32%)	(17%)	24%	9%
Packaging division	6%	5%	35%	3%	(13%)	11%	7%
Operating Profit Growth	(56%)	NM	NM	(54%)	(25%)	11%	10%
Net Income Growth	(3%)	NM	NM	(55%)	NM	2%	11%
<b>Profitability Ratios (%)</b>							
Operating margin (%)	6%	(1%)	16%	14%	12%	13%	13%
Chemistry division	6%	16%	13%	13%	13%	15%	15%
Paper division	(1%)	(11%)	20%	12%	(7%)	6%	9%
Packaging division	13%	3%	10%	15%	13%	12%	12%
EBITDA Margin %	12%	5%	18%	18%	17%	17%	17%
Net Margin (%)	11%	(31%)	14%	12%	11%	10%	11%
<b>Return Ratios</b>							
Profit Margin	11%	(31%)	14%	12%	11%	10%	11%
Asset Turnover	0.6x	0.8x	1.2x	0.6x	0.7x	1.0x	1.0x
Financial Leverage	1.5x	1.6x	1.7x	1.5x	1.4x	1.6x	1.5x
Dupont ROE (%)	10%	(39%)	28%	11%	11%	16%	16%
ROCE (%)	4%	(1%)	28%	12%	18%	18%	18%
ROA (%)	7%	(24%)	16%	7%	7%	10%	11%
<b>Leverage Ratios</b>							
Debt - Equity Ratio	0.2x	0.4x	0.2x	0.0x	0.1x	0.1x	0.1x
Net Debt - Equity Ratio	0.0x	0.0x	(0.1x)	(0.2x)	(0.1x)	(0.1x)	(0.1x)
Interest Coverage	9.1x	(1.1x)	46.8x	19.9x	nm	25.0x	35.8x
<b>Liquidity Ratios</b>							
Current Ratio	3.0x	2.5x	1.6x	2.5x	2.1x	2.2x	2.4x
Quick Ratio	2.2x	1.7x	1.2x	1.7x	1.2x	1.2x	1.4x
<b>Valuation Ratios</b>							
EV/EBITDA	5.1x	11.0x	2.2x	4.3x	5.3x	8.3x	7.7x
P/E	8.5x	nm	3.9x	8.8x	11.5x	13.1x	11.8x

Source: Research Dynamics, Bloomberg, Company data

**DISCLAIMER**

CPH Group AG ("CPH") is a client of Research Dynamics. The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. Research Dynamics is a division of Dynamics Group AG. Dynamics Group is an independent consultancy firm focused on strategic advisory, communication management and research and analysis.

This report (henceforth known as "document") has been drafted by the authors concerned as a non-binding opinion on the market situation and on the instruments of investment in question and compiled by Dynamics Group in order to provide background information about the companies. It is intended exclusively for the purpose of information.

Dynamics Group has not individually verified the information and data on which this document is based. All information and data in this document originate from generally available sources which the author concerned or Dynamics Group viewed as reliable at the time of drafting this document. However, no liability can be assumed for their correctness, accuracy, completeness and appropriateness – neither expressly nor tacitly. The contents of this document do not represent an assurance or guarantee by the authors concerned or Dynamics Group. Forward-looking information or statements in this document contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations

Dynamics Group shall not be liable for any consequential damage to properties – on whatever legal grounds it may be. Liability of Dynamics Group on account of premeditation or gross negligence shall remain unaffected by this.

Dynamics Group has no permission to provide assurances or assume guarantees on behalf of the companies or a third party mentioned in this document. Neither the companies mentioned in this document nor any other individual assumes liability for any loss, damage or detriment that may result from the use of this document, especially when taking decisions on investments, or from other reasons. Dynamics Group cannot be held responsible for detrimental consequences that occur or may occur due to the use or its omission based on the views and inferences contained in this document. Past performance trends of value, price or rates do not provide any indications to the future trends for an investment. Dynamics Group does not provide any guarantees for the suggested yield or the achievement of referred targets.

This document does neither represent an offer of purchase, holding or sale of any securities, money market instruments or of derivatives, nor does it contain the basis for a contract or a commitment of any kind. Every investment, for example, in debentures, shares and options, is associated with enormous risks. A decision on investment with regard to any security may not be based on this document. This document is neither an advice on investment, nor a recommendation or invitation for purchasing, holding or selling any securities, money market instruments or derivatives.

Dynamics Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this document. However, the respective directors, employees and contractors of Dynamics Group may hold positions in the described securities and/or options, futures and other derivatives that are based on these securities.

This document has been provided to you for information only. It may not be reproduced or distributed to others or published in any other form partially or fully.

The distribution of this document and the information contained therein may be restricted in other jurisdictions by law and persons who may come into possession of this document must be aware of possible restrictions and adhere to the same. Failure to comply with such restrictions may constitute an infringement of the laws in USA or Canada governing the securities or of the laws of any other jurisdiction.

This study is protected by the copyright laws. It may be used only for the purpose as defined in this disclaimer. Portions of the study, if quoted, must be acknowledged by indicating the source. Any use other than this shall require prior written permission by Dynamics Group. Reproduction, circulation, publication and provision of online access to the document shall be regarded as its use and the same shall require permission. Circulation of this document, especially in a foreign country, may be permitted only under the provisions of the disclaimer and the applicable regulations. Unauthorized use of the study or omission of details of the source or the acknowledgement of copyright may lead to initiation of a civil suit for damages and be liable for prosecution.

If any part or individual formulations of this disclaimer are found to be unsustainable or become unsustainable at a future date, the rest of the contents and their validity shall not be affected by it.

**Dynamics Group AG**

Utoquai 43  
CH-8008 Zürich  
Tel. +41 43 268 32 32  
Fax +41 43 268 32 39

Zeughausgasse 22  
CH-3011 Bern  
Tel. +41 31 312 28 41  
Fax +41 31 312 28 49

21, rue des Caroubiers  
CH-1227 Carouge/GE  
Tel. +41 22 308 62 20  
Fax +41 22 308 62 36

[contact@dynamicsgroup.ch](mailto:contact@dynamicsgroup.ch)

[www.dynamicsgroup.ch](http://www.dynamicsgroup.ch)